Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

100%

5 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
5(100.0%)
5Total
Phase 4(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02327702Phase 4Unknown

Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients

Role: lead

NCT02327663Phase 4Unknown

Emtricitabine for Naive Chinese Chronic Hepatitis B Patients

Role: lead

NCT02327676Phase 4Unknown

Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients

Role: lead

NCT02327715Phase 4Unknown

Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients

Role: lead

NCT02327689Phase 4Unknown

Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients

Role: lead

All 5 trials loaded